Krystexxa Chronic Gout Medication Gets Expanded FDA Approval

Rare and rheumatic disease-focused biotech Horizon Therapeutics has received expanded approval from the US Food and Drug Administration (FDA) for its gout injection Krystexxa (pegloticase) to include its co-administration with the immunomodulator methotrexate.

In a news release, Horizon said the drug combo can help more people with uncontrolled gout achieve a complete treatment response. Uncontrolled gout is defined as gout that is unmanageable and/or develops resistance to conventional therapies.